Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline

Aegis Capital Adjusts PT on Stemline (STML) to $55 Following Financing, Development Update

January 30, 2015 9:49 AM EST

Aegis Capital lowers its price target on Stemline Therapeutics (Nasdaq: STML) from $68 to $55 and maintains a Buy rating on the stock following a recent financing round and development update.

Analyst Yi Chen commented, Stemline Therapeutics recently announced that it had licensed from... More

Stemline Therapeutics' (STML) SL-701 Receives FDA Orphan Designation as Glioma Treatment

January 30, 2015 8:43 AM EST

Stemline Therapeutics (NASDAQ: STML) announced that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.

SL-701 is an enhanced immunotherapy designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that... More